IN-IAC
2.5.2024 20:01:27 CEST | Business Wire | Press release
The Indy Autonomous Challenge (IAC) will make a grand return to the Indianapolis Motor Speedway (IMS) “The Racing Capital of the World” on September 6th, 2024. The competition is set to be a landmark event, featuring a head-to-head race of the world’s fastest autonomous racecars piloted by AI driver software developed by 10 teams representing 18 top universities from North America, Europe, and Asia.
History was made at IMS in October 2021 when IAC organized the world’s first head-to-head high-speed autonomous racing competition. Since then, IAC has organized five races at iconic tracks, including Las Vegas Motor Speedway during CES and the Monza F1 Circuit in Italy. IAC and its university teams have achieved a long list of world records for high-speed ground-based autonomy. World records include the autonomous land speed record (192.2 mph), the top speed on-track (180 mph), the fastest on-track head-to-head overtake (177 mph), and most miles of autonomous racing (7,500 miles).
“Three years ago, we gathered the best and brightest minds from universities around the world to make history at Indianapolis Motor Speedway, proving that autonomous racing is possible and launching a global effort to accelerate the pursuit of high-speed autonomous mobility,” said Paul Mitchell, President of the Indy Autonomous Challenge. “After setting many records and proving that autonomous vehicles can race at extreme speeds, we are returning home to the Racing Capital of the World to attempt an even more ambitious head-to-head race.”
The upcoming race at IMS, which is being held in partnership with the Indiana Economic Development Corporation (IEDC), will be a high-adrenaline head-to-head race of multiple IAC AV-24 autonomous racecars. Teams from leading research universities worldwide will push the limits of autonomous technology, competing at breathtaking speeds on the iconic oval track. This race promises not just to entertain but to offer a glimpse into the future of mobility, where AI drivers can operate autonomous vehicles safely on highways at high speeds, reducing the risk of accidents and speeding up supply chain logistics.
“Indiana is a leader in the future of mobility, attracting new business investment, fostering R&D and inspiring innovation across EV, hydrogen and autonomy,” said Indiana Secretary of Commerce David Rosenberg. “The technologies, companies and talent being assembled by the Indy Autonomous Challenge are making significant strides in developing autonomous capabilities, putting Indiana at the forefront of tomorrow’s global economy while inspiring the next generation of leaders and risktakers.”
With 10 teams representing 18 universities from five countries, the race will be the world’s largest autonomous racing competition.
- AI Racing Tech - University of California, Berkeley (California), with University of Hawai'i (Hawai’i), University of California, San Diego (California), and Carnegie Mellon University
- Autonomous Tiger Racing - Auburn University (Alabama)
- Black & Gold Autonomous Racing - Purdue University (Indiana)
- Cavalier Autonomous Racing - University of Virginia (Virginia)
- KAIST - Korea Advanced Institute of Science and Technology (South Korea)
- Luddy Autonomous Racing – Indiana University (Indiana)
- MIT-PITT-RW - Massachusetts Institute of Technology (Massachusetts), University of Pittsburgh (Pennsylvania), Rochester Institute of Technology (New York), and University of Waterloo (Canada)
- PoliMOVE-MSU - Politecnico di Milano (Italy), Michigan State University (Michigan), University of Alabama (Alabama)
- TUM Autonomous Motorsport - Technische Universität München (Germany)
- UNIMORE Racing - University of Modena and Reggio Emilia (Italy)
“The Indianapolis Motor Speedway was originally built as a test bed for early automobiles,” said J. Douglas Boles, President of IMS. “Having teams from the world’s most elite research universities using the track to prove out the future of autonomous vehicles connects the track’s historic roots to the future of AI and robotics.”
The race will attract thousands of attendees from government, industry, and academia including 2,000 high school students studying Science, Technology, Engineering, and Math (STEM). The race event will be live-streamed worldwide for those who cannot attend in person.
“For many Hoosiers, your first trip to the Indianapolis Motor Speedway is a rite of passage,” said Indiana Secretary of Education Katie Jenner. “The Indy Autonomous Challenge provides a unique opportunity for students to visit the track and experience first-hand the incredible STEM technologies being developed right here in Indiana. We are excited to help recruit high school students to attend the event and partner in the planning of a STEM Zone that will connect them directly to future college and career opportunities.”
In addition to the “main event” head-to-head race, the day will include several interactive events and activations that will offer attendees a chance to learn about and engage with technologies of the future including autonomous vehicles, drones, robots, augmented and virtual reality, generative AI, sensor fusion, internet of things, etc. Activations will include:
- Innovation Paddock: Interactive hard-tech exhibits by industry-leading companies, start-ups, universities, and innovation-based non-profits will be located in the Trackside Garages adjacent to the track. Here, attendees can interact with the latest technology advancements in mobility, AI, automation, robotics, and more.
- Future Mobility Summit: An invitation-only summit centered around breakthrough advancements such as AI-driven autonomy, next-generation drones, smart infrastructure, and sustainable energy solutions, with a special focus on Indiana’s innovative contributions, the summit promises an unparalleled convergence of thought leaders from industry, government, and academia. This curated event, designed to spark meaningful discussions and foster policy development to accelerate the advent of future mobility, will feature dynamic keynotes and panel sessions steered by renowned figures from leading industry circles.
- STEM Zone: Created in partnership with the Indiana Department of Education and dedicated to inspiring the next generation of innovators, the STEM Zone will engage students with interactive exhibits and educational sessions focused on science, technology, engineering, and mathematics underscoring the IAC's commitment to fostering curiosity and passion for STEM among youth, highlighting the critical role of education in the future of technology. Students will also have access to Innovation Paddock exhibitions, sponsored lunch concessions, and seating in the Tower Terrace Grandstands to watch the IAC race.
Companies, governments, universities, and non-profits interested in participating in the Indy Autonomous Challenge at IMS can contact info@indyautonomouschallenge.com. High School administrators or teachers interested in bringing students to the event can contact EEL@doe.in.gov. General attendees who would like to attend the race event can purchase tickets on the Indianapolis Motor Speedway website starting May 2nd, 2024.
About the IAC: The Indy Autonomous Challenge (IAC) is a non-profit corporation based in Indianapolis, Indiana (USA) which organizes racing competitions among university-affiliated teams representing 18 universities from around the world. Teams program AI drivers to pilot fully autonomous IAC racecars and compete in a series of history-making events at iconic tracks. Based in Indiana, the IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in safety and performance of automated vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, & YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502559440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
